Premium
Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACS‐NSQIP risk calculator
Author(s) -
Schwartz Patrick B.,
Stahl Christopher C.,
Ethun Cecilia,
Marka Nicholas,
Poultsides George A.,
Roggin Kevin K.,
Fields Ryan C.,
Howard John H.,
Clarke Callisia N.,
Votanopoulos Konstantinos I.,
Cardona Kenneth,
Abbott Daniel E.
Publication year - 2020
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26071
Subject(s) - medicine , perioperative , sarcoma , calculator , nephrectomy , surgery , kidney , pathology , computer science , operating system
Background The ACS‐NSQIP risk calculator predicts perioperative risk. This study tested the calculator's ability to predict risk for outcomes following retroperitoneal sarcoma (RPS) resection. Methods The United States Sarcoma Collaborative database was queried for adults who underwent RPS resection. Estimated risk for outcomes was calculated twice in the risk calculator, once using sarcoma‐specific CPT codes and once using codes indicative of most comorbid organ resection (eg nephrectomy). ROC curves were generated, with area under the curve (AUC) and Brier scores reported to assess discrimination and calibration. An AUC < 0.6 was considered ineffective discrimination. A negative ▲ Brier indicated improved performance relative to baseline outcome rates. Results In total, 482 patients were identified with a 42.3% 90‐day complication rate. Discrimination was poor for all outcomes except “all complications” and “renal failure.” Baseline outcome rates were better predictors than calculator estimates except for “discharge to nursing or rehab facility” and “renal failure.” Replacing sarcoma‐specific CPT codes with resection‐specific codes did not improve performance. Conclusion The ACS‐NSQIP risk calculator poorly predicted outcomes following RPS resection. Changing sarcoma‐specific CPT to resection‐specific codes did not improve performance. Comorbidities in the calculator may not effectively capture perioperative risk. Future work should evaluate a sarcoma‐specific calculator.